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Abstract
ALS is a devastating neurodegenerative disease whose causes are still poorly understood. To
identify additional genetic risk factors, here we assess the role of de novo mutations in ALS by
sequencing the exomes of 47 ALS patients and both of their unaffected parents (n=141 exomes).
We found that amino acid-altering de novo mutations are enriched in genes encoding chromatin
regulators, including the neuronal chromatin remodeling complex component SS18L1/CREST.
CREST mutations inhibit activity-dependent neurite outgrowth in primary neurons, and CREST
associates with the ALS protein FUS. These findings expand our understanding of the ALS
genetic landscape and provide a resource for future studies into the pathogenic mechanisms
contributing to sporadic ALS.
11Correspondence should be addressed to: Aaron D. Gitler 300, Pasteur Drive, M322 Alway Building, Stanford, CA 94305,
650-725-6991 (phone), agitler@stanford.edu. Alessandra Chesi, 300 Pasteur Drive, M322 Alway Building, Stanford, CA 94305,
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Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a fatal adult-
onset neurodegenerative disease characterized by loss of motor neurons 1. Although ~10%
of cases have a family history of ALS (FALS), the majority of cases are sporadic (SALS).
There have been several recent advances in defining the genetic landscape of FALS. These
include discoveries of mutations in TARDBP, FUS, VCP, OPTN, UBQLN2, C9orf72, and
PFN1 as new FALS disease genes 2–8. Together with mutations in SOD1 9, the causes of
two thirds of FALS cases have now been elucidated. There have also been significant
inroads into understanding SALS etiology and now genetic contributors for ~11% of SALS
cases are known. Since it is likely that genetics plays a central role in this form of the
disease, there is intense interest in defining additional genetic causes and risk factors for
SALS.
A possible genetic mechanism for sporadic disease is de novo mutation – a mutation that
arises spontaneously in the germline of one of the unaffected parents. Indeed, de novo
mutations have recently been identified as contributors to neurodevelopmental disorders
such as autism spectrum disorders, schizophrenia, and mental retardation 10–16. There have
been confirmed de novo mutations in known ALS genes in apparently sporadic ALS
cases 17–19, indicating that, in principle, this mechanism could also contribute to ALS.
Results
To test the hypothesis that de novo mutations contribute to risk for ALS, we performed a
systematic analysis of ALS trios (ALS patient and both unaffected parents, Fig. 1a). Because
ALS is a late onset disease, trios for which DNA samples are available for patients and their
parents are much rarer than for early onset ones like autism. Nevertheless, we were able to
assemble a collection of 47 ALS trios and we performed whole exome sequencing on all 141
individuals (47 × 3 = 141 exomes). We pre-screened all 47 ALS cases for the C9orf72
hexanucleotide repeat expansion 20, 21 and they were all negative. See Supplementary Table
S1 for clinical and demographic information.
We achieved an average coverage of 56X across all samples, and on average 87% of the
target bases in each individual were covered by at least 10 independent sequence reads
(Supplementary Table S2). Following validation by Sanger sequencing we identified 25
novel de novo amino acid-altering variants (non-synonymous, NS): 20 missense, 1
nonsense, 1 splicing, 2 frameshift and 1 in-frame deletion. The observed de novo mutation
rate is consistent with those reported in recent studies of autism spectrum disorders (10–13
and see Supplementary Table S3). The frequency distribution of de novo NS mutations
closely followed a Poisson distribution, indicating that multiple de novo events within a
single individual do not contribute to ALS risk (Supplementary Fig. S1).
Table 1 shows the list of 25 novel de novo NS mutations identified in the 47 ALS trios. We
first asked if there are any functional categories or cellular pathways enriched in this list.
Functional annotation analysis performed with DAVID (v6.7) 22 revealed a significant
enrichment of genes encoding chromatin regulators (5 out of 25: EHMT1, FOXA1,
HDAC10, SRCAP, and SS18L1 (see below and Staahl et al submitted); P=1×10−2; corrected
for the multiple pathways that were tested). Are de novo mutations simply more common in
chromatin regulator genes or is this enrichment in our ALS list meaningful? To address this
question, we sought a “control” set of trios. The recent analysis of de novo mutations in
autism spectrum disorders included some exome data on unaffected siblings 10. We used the
de novo mutations found in unaffected siblings (n=50) to perform the same functional
analysis. This list of de novo mutations was not enriched for any functional category
(Supplemental Fig. S2), supporting the idea that chromatin regulator genes and defects in
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chromatin regulation could contribute to ALS. Indeed, drugs modulating histone acetylation
have shown protective effects in ALS mouse models and patient iPSC-derived motor
neurons 23–25 and have undergone phase 2 clinical studies in ALS subjects 26. Our results
now reveal potential genetic connections to ALS as well.
Three genes on the list have been implicated in neurite outgrowth (NTM, VCL,
SS18L1) 27–31. Defects in neurite outgrowth have been seen in zebrafish models of ALS 32
and in iPSC-derived motor neurons from ALS patients 25. One of these genes, SS18L1 (also
called CREST), is expressed only in post mitotic neurons and we have found encodes an
essential subunit of a neuron-specific chromatin-remodeling complex (nBAF) (Staahl et al in
press) that resembles yeast SWI/SNF and SWR and is also called mSWI/SNF 33. nBAF
controls activity-induced dendrite outgrowth 29, 31 and is strongly expressed in the brain and
spinal cord, where it localizes to the nucleus (Fig. 1c). CREST is a calcium-regulated
transcriptional activator, a property that requires the last 9 amino acids of CREST, which is
reported to interact with the histone acetylase CBP (Fig. 1b and 29). Remarkably, we
identified a de novo mutation in SS18L1/CREST that introduces a stop codon removing the
exact same last nine amino acids (p.Q388stop, Table 1 and Fig. 1b).
To determine the functional significance of this mutation in neurons, we tested its effects in
primary cortical neurons isolated from mouse embryos. Depolarizing these primary neuronal
cultures with KCl induced dramatic dendrite outgrowth (Fig. 1d), increasing the total
dendrite length (Fig. 1e) and number of dendritic branch points per neuron (Fig. 1f). We
transfected these neurons with GFP, WT CREST or a mutant CREST lacking the last 9
amino acids (CREST1–393; this truncation in the mouse CREST homolog corresponds to
CREST1–388 in human CREST, Fig. 1b). Expression of GFP or WT CREST had no effect
on KCl-induced dendrite outgrowth (Fig. 1 d–f), whereas the presence of mutant CREST
profoundly inhibited dendrite outgrowth (Fig. 1 d,e) and markedly decreased complexity of
the dendritic arbors (Fig. 1f). These functional studies in primary neurons indicate that this
mutation is likely deleterious and its dominant negative properties are consistent with a
heterozygous mutation being able to cause disease.
To further examine a genetic role for SS18L1 in ALS, we analyzed exome sequence data
from index cases of 62 ALS families that were negative for all known ALS genes including
C9orf72. In one case (individual III:2, family ALS296, Fig. 2a), we identified a novel
missense mutation (p.I123M) that was absent from public SNP and exome databases. We
also performed targeted SNP genotyping on 693 control individuals from the same
population and this variant was absent. Re-sequencing in this family showed the p.I123M
variant was absent from the unaffected parent of this index case, implying segregation of the
mutation from the affected (deceased) parent (Fig. 2a). To test the functional significance of
this variant and to extend our studies to a cell type more clinically relevant to ALS, we
tested its effects in cultures of primary motor neurons isolated from mouse embryos. We
transfected motor neurons with GFP, WT CREST or the two mutants (CREST1–393 or
CRESTI123M). Strikingly, compared to GFP or WT CREST, expression of the mutants
CREST1–393 or CRESTI123M significantly blocked depolarization-induced dendrite
outgrowth (Fig. 2b) and the increase in dendritic arbor complexity (Fig. 2c). Thus, these
functional experiments in primary motor neurons provide evidence to support the
pathogenicity of the two CREST variants identified in ALS patients.
The defects in dendritic morphology elicited by the two SS18L1/CREST mutant proteins in
our primary neuron experiments are strikingly reminiscent of dendrite patterning defects
observed in neurons cultured from FUS-deficient mice 34. We therefore considered the
possibility that FUS and SS18L1 might physically associate. We (GRC and LE) conducted
mass spectrometry studies of nBAF complexes affinity purified at low stringency (150 mM
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NaCl, 0.1% NP-40, 50mM Tris-HCL, pH 8.0) from P1 cortical neurons for proteins that
interact with nBAF in cortical neurons. We detected 81 peptides from FUS representing 29.6
% coverage in these mass spectrometry studies. To further explore the potential physical
interaction of FUS and CREST, we performed immunoprecipitation assays from nuclear
extracts isolated from P1 mouse cortical neurons. Immunoprecipitating endogenous CREST
from these extracts followed by immunoblotting with a FUS antibody demonstrated that
CREST and FUS interact in neurons (Fig. 2d). We noted the interaction between CREST
and FUS, when using the reciprocal immunoprecipitation (FUS antibody for IP, SS18L1/
CREST antibody for immunoblot), was nearly undetectable. This could be indicative of
different relative abundances. FUS might be more abundant than CREST and therefore we
detect the interaction only one way. Another possibility is that the FUS antibody masks the
binding site of CREST on FUS. To address this we performed quantitative western blots to
determine the amounts of FUS and Brg (the core ATPase was used as a representative of the
nBAF complexes of which CREST is a core subunit) per cell. We estimate there to be 3×105
molecules of BRG and 1.2×106 molecules of FUS per cell (data not shown). Therefore, FUS
is at least 4-fold more abundant, and not a core BAF complex component, but perhaps
transiently associates with CREST perhaps in a regulatory role. Because CREST is a
dedicated subunit of the nBAF complex in neurons we wondered if using antibodies against
other nBAF subunits would immunoprecipitate FUS. Indeed, we find many of the BAF
subunits co-immunoprecipitate FUS (Figure 2e). Interestingly, Polybromo, which is a PBAF
complex subunit and does not contain CREST, co-immunoprecipitated FUS. Therefore, FUS
must be binding to a surface on the BAF complex other than CREST. This surface might be
on Brg or BAF57 as these IPs co-immunoprecipated FUS the weakest and therefore the
antibodies to these subunits could be blocking the nBAF-FUS interaction. Together, these
experiments provide evidence that CREST and the nBAF chromatin remodelling complex
can associate with FUS in neurons.
Intriguingly, bioinformatics analysis revealed the presence of predicted prion-like domains
in SS18L1 and SS18 (Fig. S3). These domains are present in an expanding class of
neurodegenerative disease proteins, including TDP-43, FUS, TAF15, EWSR1,
hnRNPA2B1, and hnRNPA1, and are able to drive aggregation of these proteins 35–40. In
the future, it will be important to define how SS18L1’s prion-like domain contributes to its
normal function and if it facilitates co-aggregation with FUS or other aggregation-prone
RNA-binding proteins in disease. Together, these data support a potential role of the
identified SS18L1/CREST variants in ALS and implicate additional nBAF complex
components as candidates for further investigation in the disease.
Discussion
We have sequenced the exomes of 47 ALS trios. These results provide a systematic analysis
of de novo mutations in ALS and reveal genes encoding chromatin regulators as new
candidates for ALS genetic contributors. Notably, in addition to SS18L1, we identified a de
novo truncating mutation in SRCAP in another ALS trio (Table 1). Like SS18L1/CREST,
SRCAP is also a CBP-interacting transcriptional co-activator 41, further underscoring a
potential role of CBP-associated chromatin regulators in ALS. Indeed, FUS itself is a key
transcriptional regulator via interactions with CBP 42. Mutations in 8 of 15 subunits of BAF
complexes have been identified as causative in Coffin-Siris, a rare congenital anomaly
syndrome characterized by growth deficiency, intellectual disability, microcephaly, coarse
facial features and hypoplastic nail of the fifth finger and/or toe 43, 44, and Nicolaides-
Baraitser Syndromes, which includes features of intellectual disability with marked language
impairment, microcephaly, epilepsy and morphological defects 45, 46 and have also been
found in sporadic autism 10 and intellectual disability 47 as well as schizophrenia 48. It is
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tempting to speculate about possible pathophysiological connections between
neurodevelopmental and neurodegenerative disorders 49.
Beyond the chromatin regulator genes, the identification of a de novo mutation in the type
XIX collagen gene COL19A1 is intriguing because the expression of this molecule has been
recently shown to be markedly upregulated in the muscle at end-stage of disease in a mouse
model of inherited ALS (SOD1G39A) and Col19a1 expression negatively correlates with
survival 50. Future studies will be required to define the effect of this variant on COL19A1
expression and the effect it has on muscle function during disease progression.
Additional functional studies in cell culture and animal models as well as re-sequencing
these genes in larger ALS patient populations will be needed to assess the pathogenicity of
the genes identified in this study. We propose that the specific genes we identify here, as
well as their network of interacting partners (genetic and physical interactions), especially
the other components of the SS18L1/CREST-containing nBAF chromatin remodeling
complex are now candidates for evaluation in larger ALS patient cohorts. Using the autism
exome sequencing efforts as a guide 10–13, we anticipate that increasing the number of ALS
trios analyzed, integrating data from multiple studies, and focusing on key nodes in protein
interaction networks will help strengthen and focus disease gene discovery efforts. Finally,
this approach could be applied broadly to other neurodegenerative diseases, such as
Parkinson disease and Alzheimer disease.
Online Methods
ALS trios
Details of the ALS patients used in this study are compiled in Table S1. Genomic DNA from
human ALS patients and both of their unaffected parents was collected at Emory University
School of Medicine (IRB# IRB-133-98) and the Johns Hopkins University School of
Medicine. ALS samples were verified to meet El Escorial criteria for definite or probable
ALS.
Exome capture, alignments and base-calling
Exomes for the 47 trios were captured with Agilent SureSelect Human All Exon 50Mb.
Libraries were indexed, pooled and sequenced on Illumina HiSeq2000 machines (paired-
end, 100-bp reads, 5 or 6 libraries per lane). Reads were mapped to a custom GRCh37/hg19
build using BWA 0.5.9 51. Picard-tools 1.55 was used to flag duplicate reads (http://
picard.sourceforge.net/). GATK (v1.3-2-gcdd40d1) 52 IndelRealigner was used to realign
reads around insertion/deletion (indel) sites. Read qualities were recalibrated using GATK
Table Recalibration. Genotypes were generated simultaneously for all samples with GATK
Unified Genotyper. Variant quality score recalibration was performed on SNPs calls (using
HapMap v3.3 and the Omni chip array from the 1000 Genomes Project as training data) and
calls were filtered at 99.0 truth sensitivity level 53. Raw indel calls were filtered using
FILTER= “QD < 2.0 || ReadPosRankSum < −20.0 || InbreedingCoeff < −0.8 || FS > 200.0”.
Predicted de novo events were identified as sites where both parents were homozygous for
the reference sequence and the offspring was heterozygous. Paternity and maternity was
verified by checking the percentage of shared heterozygous mutations between child and
mother or father in each trio (~50%). To identify rare private variants (novel), the full
variant list was compared against dbSNPv135, the NHLBI Exome Sequencing Project (ESP
5400) and the 1000 Genomes Project (Feb 2012). Annotation was performed using
ANNOVAR (http://www.openbioinformatics.org/annovar).
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Sanger sequencing validation of variants
All amino acid-altering de novo novel events were validated by designing primers with
Primer3 (v.2.3.0) followed by PCR amplification and Sanger sequencing of father, mother
and proband DNA samples.
Functional enrichment analysis
Functional enrichment analysis was performed with the Functional Annotation Chart tool of
DAVID v. 6.7 54 using the human genome as background. P-values were calculated using a
modified Fisher Exact Test 55 and corrected using Bonferroni correction for multiple
comparisons.
Sequence analysis of Familial ALS cases
Index cases from 62 ALS families were recruited through neurogenetic clinics at Concord
Hospital, Sydney, as well as at the Molecular Medicine Laboratory, Concord Hospital, a
referral centre for ALS DNA diagnostic testing. Most families were of European descent.
DNA samples from 693 control individuals were obtained from the Australian MND DNA
Bank. Patients and family members provided informed written consent regulated by the
Human Research Ethics Committee of the Sydney South West Area Health Service. All
families had previously been screened for mutations in known ALS genes including
C9ORF72, TARDBP, SOD1, FUS, PFN1, OPTN, VCP, UBQLN2, ANG, FIG4, DCTN1,
and CHMP2B.
Exomes for familial cases were captured with Illumina TruSeq Exome Enrichment kit.
Libraries were indexed, pooled and sequenced on Illumina HiSeq2000 instruments (paired-
end, 100-bp reads, 6 libraries per lane). Reads were mapped to the human genome (hg19,
Genome Reference Consortium Human Build 37) using BWA.
Clinical and demographic data
Family ALS296 was of UK ancestry. The index case (individual III:2, Fig. 2a) was
diagnosed with bulbar onset ALS at 35 years, disease duration of 1 year. The father of this
index case (individual II:2, Fig. 2a) was diagnosed with bulbar onset ALS at 48 years,
disease duration of 1 year. Individual II:1 (Fig. 2a) was diagnosed with limb onset ALS and
died at 61 years.
Immunohistochemistry
Formalin-fixed, paraffin-embedded human spinal cord sections, obtained from the
University of Pennsylvania Center for Neurodegenerative Disease Research Brain Bank,
were rehydrated and subjected to Antigen Retrieval with Citrate Buffer pH 6.0 (Vector
Labs). After washing with 0.1% PBS-Tween blocking was performed with 2% BSA, 5%
NGS, 0.1% PBS-T for 60 minutes at 25°C. Sections were incubated with Rabbit anti-
CREST (1:50; Proteintech) in 0.1% PBST overnight at 4°C. After washing with 0.1%
PBST, sections were incubated with Goat anti-Rabbit-568 IgG (1:500; Invitrogen) for 2 hour
at 25°C. Sections were then incubated DAPI, washed with PBS and mounted with 4% n-
Propyl gallate (Sigma) in 90% glycerol, 10% phosphate buffered saline (PBS).
Mouse primary neuron culture and transfection
All mouse experiments were performed in compliance with institutional guidelines and
regulations. E18.5 cortical neurons were isolated using the MACSTM neuron isolation kit.
Motor neurons were isolated from E12.5 mouse spinal cord using Papain Dissociation
System (Worthington). Dissociated cells were transfected with GFP or other constructs
using Nucleofector (Amaxa shuttle) before plating on poly-L-ornithine, Laminin and
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fibronectin coated coverslips. Cortical neuron culture media contained DMEM/F12 with
putrescine, 2-mercaptoethanol, transferrin, insulin, selenium, progesterone, MEM vitamin
additive and 5% FBS. Motor neuron culture media contained Neurobasal supplemented with
B27 (Invitrogen), 2% horse serum, L-glutamine (0.5 mM), L-glutamate (25 μM), BDNF (1
ng/ml), GDNF (100 pg/ml) and CNTF (10 ng/ml).
Dendrite outgrowth assay
CREST, CREST1–393, or CRESTI123M were cloned into the pCIG-IRES-eGFP plasmid.
50ng of the respective plasmids mixed with 450ng pCIG-IRES-eGFP plasmid was
transfected into 250,000 dissociated E18.5 mouse cortical neurons or E12.5 mouse motor
neurons using Nucleofector (AMAXA shuttle) and plated onto coated coverslips. The neural
cultures were grown for 6 days, +/− 30mM KCl for the last day. To define dendrite
structure, cultures were fixed with 4% PFA and stained with anti-GFP (Molecular Probes)
and anti-MAP2 (Sigma) and Alexa-Flour-488, -568 (Invitrogen) secondary antibodies
(1:1000) and DAPI and mounted as described above. Pictures of GFP+/MAP2+ neurons
were taken with a Leica DM5000 fluorescent microscope. Dendrite analysis was done with
ImageJ and NeuronJ software.
Co-immunoprecipitation
For co-IPs, antibodies against FUS (A300-293A), BAF250B (A301-046A), Polybromo
(A301-590A), BAF57 (A300-810A), BAF170 (A301-039A) all from Bethyl, CREST (H-80)
from Proteintech, Brg (G7 or H88), BAF250A (H90x) all from Santa Cruz, BAF60c and
BAF45c, BAF155-3 from the Crabtree lab were used. Rabbit or mouse IgG antibodies from
Santa Cruz were used as a control. P1 mouse cortices were isolated using standard
procedures. Nuclear extracts were prepared and incubated with respective antibodies and
Protein A or G dynabeads overnight and washed 6 times in PBS/0.1% Triton X-100 as
described in 56. Western blots were probed with antibodies to Fus (ab23439) from Abcam,
Brg (G7) and CREST (M15) from Santa Cruz. LiCor secondary antibodies were used for
detection.
Statistical Analysis
For the functional enrichment analysis in ALS and control trios we used the Functional
Annotation Chart tool of DAVID v. 6.7 54 with the human genome as background. P-values
were calculated using a modified Fisher Exact Test 55 and corrected using Bonferroni
correction for multiple comparisons. For the primary neuronal culture assays we used the
unpaired two-sided Student’s t-test. The number of biologically independent experiments
and P-values are indicated in the figure legends. The sample sizes were chosen according to
standard practice in the field.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
The SS18L1/CREST de novo mutation (Q388stop) identified in an ALS trio inhibits
activity-dependent dendritic outgrowth. a) We sequenced the exomes of 47 ALS patients
and both unaffected parents (n = 141 exomes) to identify de novo mutations. b) We
identified a de novo mutation in the neuronal chromatin remodeling complex subunit
SS18L1/CREST, which introduces a premature termination codon, deleting the CBP-
binding motif contained within the last nine amino acids. h=human; m=mouse. c) SS18L1/
CREST is expressed in motor neurons of the adult spinal cord and localizes to the nucleus
(arrow). Scale bar 10 μm. d) Functional validation of the CREST de novo mutation in
primary neurons. Primary cortical neurons were isolated from E18.5 mouse embryos,
transfected with Vector-IRES-GFP, CREST-IRES-GFP or CREST AA 1–393-IRES-GFP (The
1–393 truncation of mouse CREST corresponds to 1–388 of human CREST, which we
identified in the ALS trio as Q388stop). Neurons were cultured for 5 days and stimulated
overnight with 30mM KCl where indicated. Control vector and CREST overexpression do
not affect dendrite outgrowth in response to KCl depolarization. CREST AA 1–393
significantly reduces total dendrite length in response to KCl depolarization. An example of
the dendrite outline tracing used to quantify dendritic length and number of branch points is
shown. Scale bar 10 μm. e) The average values are from three independent experiments,
each with three coverslips per condition with 15–20 GFP+ neurons scored per coverslip. f) #
branch points per cell is affected in a similar fashion as total dendrite length. Error bars, S.E.
*P<0.02, **P<0.002, ***P<0.0005, Student’s t-test.
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Figure 2.
Identification of an additional SS18L1/CREST variant in FALS case and interaction with
FUS. a) Novel SS18L1 missense variant in familial ALS. Genotypes of available DNA
samples for the indicated SS18L1 variant are shown (‘wt’ denotes wild type, ‘I123M’
denotes mutant). The variant c.T369G (p.I123M) was identified in affected individual III:2
(the index case) and was absent in unaffected individuals II:3 and III:1. The genotype of
sample II:2 (*) was inferred from the genotypes of spouse and progeny. The question mark
(?) for individual I:2 indicates that no historical clinical notes were available. b) Motor
neurons transfected with GFP or WT CREST respond to KCl stimulation by increasing the
total dendritic length. Transfection of CREST1–393 or CRESTI123M inhibits stimulation-
induced dendrite outgrowth. The average values are from two independent experiments,
each with four coverslips per condition with 30–35 GFP+ neurons scored per coverslip. c) #
of branch points in motor neurons is affected in a similar fashion as total dendrite length.
Error bars, S.E. *P<0.02, **P<0.002, ***P<0.0005, Student’s t-test. d,e) FUS and SS18L1/
CREST can physically associate in mouse cortical neurons. d) As a positive control, nBAF
complex core subunit Brg, was co-immunoprecipitated by SS18L1/CREST. The SS18L1/
CREST antibody also co-immunoprecipitated FUS. e) Antibodies against several other
nBAF subunits co-immunoprecipitate FUS. * FUS band is visible.
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